Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 4/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10870464 | 0.95 | MME (0.56) | LTA4HMMECTRB1ACECPA1 | |
| SCHEMBL31181218 | 0.95 | MME (0.56) | LTA4HMMECTRB1ACECPA1 | |
| SCHEMBL10866909 | 0.95 | MME (0.56) | LTA4HMMECTRB1ACECPA1 | |
| SCHEMBL30799883 | 0.92 | MME (0.56) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL11799997 | 0.92 | MME (0.56) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL10646220 | 0.92 | MME (0.58) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL29470194 | 0.92 | MME (0.58) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL29531510 | 0.92 | MME (0.58) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL10646215 | 0.92 | MME (0.58) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL30799836 | 0.92 | BACE1 (0.64) | BACE1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | BACE1 10/4885LTA4H 4132/4885MME 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.